Online inquiry

IVTScrip™ mRNA-Anti-MSTN, PF-06252616(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ13278MR)

This product GTTS-WQ13278MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets MSTN gene. The antibody can be applied in Duchenne muscular dystrophy (DMD) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_005259.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2660
UniProt ID O14793
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-MSTN, PF-06252616(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ13278MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ5572MR IVTScrip™ mRNA-Anti-CD33, CDP-771(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA CDP-771
GTTS-WQ4124MR IVTScrip™ mRNA-Anti-ICAM1, BI-505(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA BI-505
GTTS-WQ259MR IVTScrip™ mRNA-Anti-EPCAM, 17-1A(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA 17-1A
GTTS-WQ12673MR IVTScrip™ mRNA-Anti-FZD1&FZD2&FZD5&FZD7&FZD8, OMP-18R5(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA OMP-18R5
GTTS-WQ15625MR IVTScrip™ mRNA-Anti-TNFRSF13C, VAY-736(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA VAY-736
GTTS-WQ7343MR IVTScrip™ mRNA-Anti-VTCN1, FPA-150(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA FPA-150
GTTS-WQ3304MR IVTScrip™ mRNA-Anti-lukG&lukH, ASN-100(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA ASN-100
GTTS-WQ14484MR IVTScrip™ mRNA-Anti-CNR1, RYI-018(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA RYI-018
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW